Subscribe
Share
Share
Embed
Science in Real Time (ScienceIRT) podcast serves as a digital lab notebook—an open-access, conversational platform that brings the stories behind cutting-edge life science tools and techniques into focus. From biologics to predictive analytics and AI-powered innovation, our guests are shaping the future of therapeutic discovery in real time.
Welcome back to Science in Real Time, I'm Carli Reyes and this is Funding Focus, your monthly lens on the business moves shaping biotech and drug discovery. Each episode, we spotlight the deals, policies and innovations that are driving science forward, from billion dollar pharma bets, to AI platforms raising capital, to even governments rewriting the rules of the game. This month's lineup really captures the full spectrum of how discovery is funded and scaled. Today, we'll cover: How Novo Nordisk's $550,000,000 leap into self replicating RNA The UK's plan to cement itself as Europe's biotech hub, Phenomic AI's $20,000,000 raise proving how imaging and AI are converting, and finally the bigger picture of how public and private fundings are shaping biotech's global ecosystem. Each of these stories shows how capital and policy are converging to accelerate discovery.
Carli:Let's start with our first story. Novo Nordisk has signed a $550,000,000 partnership with Replicate Biosciences to co develop self regulating RNA therapies for metabolic diseases. Three years ago, sRNA was still viewed as experimental, with most investments clustered in vaccines. By the 2024, early clinical data from smaller players proved the modality's durability, and now with this deal Novo Nordisk is really betting on scaling sRNA into mainstream cardiometabolic care, Another clear signal that RNA platforms have moved from niche to a core pillar of biopharma strategies. Across The Atlantic, the UK government announced a bold 1,120,000,000 industrial strategy to make Britain's Europe's top biotech hub by 2030.
Carli:So the timeline here matters. Post Brexit, so from 2019 to 2021, UK biotech saw a real slowdown in foreign capital. By the 2024, recovery was underway but investments still lagged behind The US. Now, this package that includes £600,000,000 for a national health data research service and £520,000,000 for biomanufacturing is meant to supercharge the rebound and create a self sustaining ecosystem. With this push, The UK is trying not to just catch up, but to set itself up as Europe's innovation hub for the next decade.
Carli:In financing news, Phenomic AI, a Toronto based startup, closed a $20,000,000 Series A to scale its imaging powered drug discovery platform. Back in 2022, imaging based phenotypic screens were mostly academic demonstrations. By 2024, pharma started to take notice, with a handful of early partnerships. Now, Phenomics' race shows the space has really matured into an investable commercial category. Phenomic combines high content cell imaging with machine learning to map tumor microenvironments and identify novel oncology targets.
Carli:Its success validates the broader industry shift towards AI and imaging workflows. What AI is to imaging is no longer a SI tool. It's clear that it's becoming an engine for modern drug discovery, as highlighted by these stories. So to close, why don't we zoom out a little bit? What ties these stories together is the interplay between the public and the private capital.
Carli:Three years ago, biotech was in a pandemic driven funding boom, with record breaking ventures all around. By the 2024, the cycle had corrected. Start ups tightened spends, and government stepped back into the gap with industrial strategies. Now, in mid-twenty twenty five, we're seeing something new public and private investment strategies converging. Government packages like The UK are designed to attract VC follow-up funding, while pharma's billion dollar deals are being de risked by early public sector investments in new modalities like RNA and AI.
Carli:Rather than operating in silos, capital sources are feeding into one another, creating an interlinked ecosystem that could sustain biotech throughout its next growth cycle. When you take a step back, what stands out this month is how different forces pharma strategies, national policies, start up capital, and even public funding are all moving now in sync. RNA is being scaled, imaging is being validated, and governments are actively positioning their economies around biotech growth. It's rare to see alignments across stakeholders at this level, but it may be exactly what's needed to push discovery into the next phase. As we look to September, two threats are worth watching closely.
Carli:First, AI biotech partnerships are heating up. We should be expecting more joint ventures before the year ends. Second, new governments and R&Ds packages that are due in both The US and Asia, which could rebalance where the next wave of biotech startups decide to launch. Both trends are closely linked to shape how fast and where discovery is scaled next, and we'll be here to track it all. And that's a wrap for this month's Funding Focus.
Carli:If you found this helpful, share it with a colleague, follow the show, and stay tuned for next updates. I'm Carli Reyes, thanks for listening.